ok - prima is one of the best on asx, page-5

Exposure is the key to grow under the shadow of Dendreon.

Quite a unique situation which has never before been seen with an Australian listed biotech and for this reason I remain of very firm belief over the next 12-24 months we will see some very surprising sp increases.

Dendreon is only now starting to get huge positive exposure for their provenge treatment and new calls for $100 are very valid since the medicare decision imo. Analysts are now predicting they will be over $55 before June.

On a comparative scale a $100 Dendreon share would be equivilent to a Prima share being worth $15.98

I would accept these figures sound ridiculous to some but then I'm sure exactly 2 years ago $2.60 Dendreon holders would've thought the same thing.

Immunotherapy treatment is a huge break through and holds a lot of hope for many cancer sufferers around the world, not just those suffering from Prostate or Ovarian cancer.